

Special Issue

State of the Art on Demyelinating Diseases in Latin America

Message from the Guest Editors

Demyelinating disorders, including Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), MOG antibody-associated disease (MOGAD), Acute Disseminated Encephalomyelitis (ADEM), and other inflammatory entities that affect the CNS, present a host of challenges, from their initial differential diagnosis to their complex management utilizing state-of-the-art therapies. All of the aforementioned inflammatory diseases are commonly identified in Latin American countries; in particular, regional frequencies of MS and NMOSD are increasing, and the socioeconomic impact on local health systems is considerable. This Special Issue aims to provide a forum for Latin American investigators to share their findings and observations on the topics of pathogenesis and mechanism of demyelinating diseases, genomics, bioimaging, biomarkers, use of biosimilar therapies, acute and symptomatic management, and molecular-targeted therapies including monoclonal antibodies for disease modification. We are seeking high-quality papers on laboratory medicine research, as well as preclinical and clinical trials and studies.

Guest Editors

Prof. Dr. Víctor M. Rivera

Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA

Dr. Liliana Patrucco

Centro de Esclerosis Múltiple de Buenos Aires, Buenos Aires, Argentina

Deadline for manuscript submissions

31 July 2026



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/265736

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.2 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).